In cases of glucose and glutamine deficiency, c-Myc binds to the GLS-AS promoter and transcriptionally represses GLS-AS, and low expression of GLS-AS is associated with poor clinical outcomes in pancreatic cancer patients [95]. This evidence concerns the gene MYC and pancreatic neoplasm.